ShapeTX Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 85

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $112M

  • Investors
  • 12

ShapeTX General Information

Description

Developer of programmable RNA medicines designed to repair the genetic causes of disease. The company offers AI-powered RNA design, precise tissue targeting, and scalable manufacturing technologies, enabling researchers and healthcare providers to create safe, effective, and customizable RNA therapies for a broad range of genetic conditions.

Contact Information

Website
www.shapetx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 700 Dexter Avenue North
  • Seattle, WA 98109
  • United States
+1 (628)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Healthcare Technology Systems
Corporate Office
  • 700 Dexter Avenue North
  • Seattle, WA 98109
  • United States
+1 (628)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ShapeTX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 15-Jul-2021 $112M Completed Generating Revenue
2. Early Stage VC (Series A) 27-Aug-2019 Completed Generating Revenue
1. University Spin-Out 01-May-2018 Completed Startup
To view ShapeTX’s complete valuation and funding history, request access »

ShapeTX Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A-2
Series A-1 44,999,982 $0.000100 8% $0.67 $0.67 1x $0.67 17.3%
To view ShapeTX’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

ShapeTX Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of programmable RNA medicines designed to repair the genetic causes of disease. The company offers AI-powered
Drug Discovery
Seattle, WA
85 As of 2025

Waltham, MA
 

Vancouver, WA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ShapeTX Competitors (8)

One of ShapeTX’s 8 competitors is Affinia Therapeutics, a Venture Capital-Backed company based in Waltham, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Affinia Therapeutics Venture Capital-Backed Waltham, MA
Capsigen Venture Capital-Backed Vancouver, WA
Capsida Biotherapeutics Venture Capital-Backed Thousand Oaks, CA
WaVe Life Sciences Formerly VC-backed Cambridge, MA
Korro Bio Formerly VC-backed Cambridge, MA
You’re viewing 5 of 8 competitors. Get the full list »

ShapeTX Patents

ShapeTX Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026193218-A1 Capsid mutations for aav production Pending 12-Mar-2025
WO-2026073032-A1 Constructs for improved aav production Pending 27-Sep-2024
WO-2026060273-A1 5' untranslated regions (utrs) for enhanced payload expression Pending 13-Sep-2024
WO-2026044087-A1 Increased cellular stability for aav production Pending 21-Aug-2024
WO-2026036118-A1 Engineered aav capsid polypeptides and methods of use Pending 09-Aug-2024 C07K14/005
To view ShapeTX’s complete patent history, request access »

ShapeTX Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ShapeTX Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cherubic Ventures Venture Capital Minority
Decheng Capital Venture Capital Minority
Willett Advisors Family Office Minority
Breton Capital Ventures Venture Capital Minority
CureDuchenne Ventures Corporate Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

ShapeTX FAQs

  • When was ShapeTX founded?

    ShapeTX was founded in 2018.

  • Where is ShapeTX headquartered?

    ShapeTX is headquartered in Seattle, WA.

  • What is the size of ShapeTX?

    ShapeTX has 85 total employees.

  • What industry is ShapeTX in?

    ShapeTX’s primary industry is Drug Discovery.

  • Is ShapeTX a private or public company?

    ShapeTX is a Private company.

  • What is the current valuation of ShapeTX?

    The current valuation of ShapeTX is .

  • What is ShapeTX’s current revenue?

    The current revenue for ShapeTX is .

  • How much funding has ShapeTX raised over time?

    ShapeTX has raised $148M.

  • Who are ShapeTX’s investors?

    Cherubic Ventures, Decheng Capital, Willett Advisors, Breton Capital Ventures, and CureDuchenne Ventures are 5 of 12 investors who have invested in ShapeTX.

  • Who are ShapeTX’s competitors?

    Affinia Therapeutics, Capsigen, Capsida Biotherapeutics, WaVe Life Sciences, and Korro Bio are some of the 8 competitors of ShapeTX.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process